ASH Press Briefing 4, Monday December 11, 2023 Late Breaking Abstracts
ASH Press Briefing 1, Saturday December 9, 2023
.
-
Abstract 901 Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool
-
Abstract 1057 Understanding the Experiences of Patients with Sickle Cell Disease and Their Caregivers By Social Media Listening in the UK
-
Abstract 157 An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial
-
Abstract 220 CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients
LBA1 Daratumumab (DARA) + Bortezomib, Lenalidomide, & Dexamethasone (VRd) vs Vrd Alone: Primary Results of the Perseus Trial
Das Laden von Vimeo wurde nicht erlaubt. Bitte ändern Sie die Datenschutz-Einstellungen
LBA2 Ibrutinib Combined with Venetoclax in Patients with RR Mantle Cell Lymphoma: Primary Analysis Results (Sympatico Study)
Das Laden von Vimeo wurde nicht erlaubt. Bitte ändern Sie die Datenschutz-Einstellungen
LBA-4 Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507
Das Laden von Vimeo wurde nicht erlaubt. Bitte ändern Sie die Datenschutz-Einstellungen
LBA-5 Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
Das Laden von Vimeo wurde nicht erlaubt. Bitte ändern Sie die Datenschutz-Einstellungen
Copyright 2024. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close